Thomas J. Lynch

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor ge...

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic<i>EGFR</i>Mutations

Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR ...

Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells

Molecular analysis of circulating tumor cells from the blood of patients with lung cancer offers the possibility of monitoring changes in epithelial tumor genotypes during the c...

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors.